Core Viewpoint - The company, 开拓药业-B (09939), announced that its chairman and CEO, Dr. Tong Youzhi, has increased his stake in the company by purchasing 4.7 million shares for approximately HKD 10.82 million, reflecting confidence in the company's future growth and commercialization potential [1]. Group 1: Share Purchase Details - Dr. Tong acquired the shares through his wholly-owned company, KT International Investment Limited, in the open market at an average price of HKD 2.30 per share, with a price range between HKD 1.89 and HKD 2.81 [1]. - This purchase represents approximately 0.9425% of the company's total issued share capital as of the announcement date [1]. Group 2: Management Confidence - Dr. Tong expressed strong confidence in the overall development prospects and commercialization transformation of the company [1]. - The board believes that this share purchase demonstrates Dr. Tong's firm belief in the clinical progress and growth potential of the company's innovative topical drugs, particularly in the hair loss treatment pipeline [1]. - The company maintains sufficient public float after this share purchase, indicating a stable shareholder structure [1].

董事会认为，本次增持事项彰显童博士对本公司的外用创新药特别是防脱生发管线的临床进展和产品商 业化的前景及增长潜力的坚定信心，以及对本公司长期投资价值的充分认可。 智通财经APP讯，开拓药业-B(09939)发布公告，本公司董事会获童友之博士(童博士，为本公司董事会 主席、执行董事兼行政总裁)通知，其于2025年11月17日至2026年1月23日(包括首尾两日)通过其全资拥 有公司KT International Investment Limited 于公开市场以自有资金约1082万港元(平均成交价格为每股 2.30 港元，增持价格区间为每股1.89港元至2.81港元)增持本公司470万股股份(本次增持事项)，占本公司 于本公告日期已发行股本总额约 0.9425%。根据本公司可获得的公开资料及就董事会所知，于本次增持 事项后，本公司仍旧维持已发行股份的充足公众持股量。 童博士表示，彼对本集团的整体发展前景及商业化转型充满信心。在符合适用法律及监管规定的情况 下，童博士不排除彼于静默期后(2026年3月26日后)择机进一步增持本公司股份。 ...